Baclofen to Reduce Alcohol Use in Veterans With HCV
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Hepatitis C (HCV) is the most common blood born virus in the United States, affecting 1.8% of
the general population and more than 5% of Veterans using VA facilities. As Veterans with HCV
have high rates of co-morbid alcohol use disorders that accelerate greatly the liver damage
caused by HCV, a safe and effective treatment for alcohol use disorders is needed. Baclofen
is a novel treatment for alcohol use disorders that has minimal effect on the liver and may
represent a safe and efficacious treatment option for Veterans with HCV and co-morbid alcohol
use disorders.